NfL Blood Biomarker Captures Suboptimal Treatment Response in MS

Measuring levels of neurofilament light chain is an effective way of detecting disease activity and the need to optimize treatment in patients with multiple sclerosis, independent of other measures, a new study shows.
Medscape Medical News

Source link

Related posts

The case for testing serum neurofilament light protein in MS


Chemotherapy: Can It Negatively Affect Your Brain?


Top Brain Games that Improve a Student's Focus and Attention


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy